Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy

References

• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crin∫ L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Onno M, Guillaudeux T, Amiot L, Renard I, Drenou B, Hirel B, Girr M, Semana G, Le Bouteiller P, Fauchet R. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol 1994; 41:79-86; PMID:7836069; http://dx.doi.org/10.1016/0198-8859(94)90089-2
   PubMed Web of Science ®Google Scholar
• McMaster MT, Librach CL, Zhou Y, Lim KH, Janatpour MJ, DeMars R, Kovats S, Damsky C, Fisher SJ. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995; 154:3771-8; PMID:7706718
   PubMed Web of Science ®Google Scholar
• Zhou J-h, Ye F, Chen H-z, Zhou C-y, Lu W-g, Xie X. Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci 2006; 78:2643-9; PMID:16434060; http://dx.doi.org/10.1016/j.lfs.2005.10.039
   PubMed Web of Science ®Google Scholar
• Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159:817-24; PMID:11549573; http://dx.doi.org/10.1016/S0002-9440(10)61756-7
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih I-M, Davidson B. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Archiv 2006; 449:31-9; PMID:16541284; http://dx.doi.org/10.1007/s00428-005-0144-7
   PubMed Web of Science ®Google Scholar
• Guerra N, Lacombe M-JT, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001; 61:6838-45; PMID:11559559
   PubMed Web of Science ®Google Scholar
• El-Chennawi F, Auf F, El-Diasty A, El-Daim M, El-Sherbiny S, Ali A, El-Baz M, El-Hameed M, Paul P, Ibrahim E. Expression of HLA-G in cancer bladder. Egyp J Immunol/Egyp Associat Immunol 2004; 12:57-64; PMID:16734140
   Google Scholar
• Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63:4107-11; PMID:12874014
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Long EO. A Human Histocompatibility Leukocyte Antigen (HLA)-G–specific receptor expressed on all natural killer cells. J Exp Med 1999; 189:1093-100; PMID:10190900; http://dx.doi.org/10.1084/jem.189.7.1093
   PubMed Web of Science ®Google Scholar
• Colonna M. Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Immunol Rev 1997; 155:127-33; PMID:9059888; http://dx.doi.org/10.1111/j.1600-065X.1997.tb00945.x
   PubMed Web of Science ®Google Scholar
• Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7:273-82; PMID:9285411; http://dx.doi.org/10.1016/S1074-7613(00)80529-4
   PubMed Web of Science ®Google Scholar
• Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007; 58:267-74; PMID:17673327; http://dx.doi.org/10.1016/j.lungcan.2007.06.011
   PubMed Web of Science ®Google Scholar
• Yie S-m, Yang H, Ye S-r, Li K, Dong D-d, Lin X-m. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007; 14:2721-9; PMID:17564748; http://dx.doi.org/10.1245/s10434-007-9464-y
   PubMed Web of Science ®Google Scholar
• de Kruijf EM, Sajet A, van Nes JGH, Natanov R, Putter H, Smit VTHBM, Liefers GJ, van den Elsen PJ, van de Velde CJH, Kuppen PJK. HLA-E and HLA-G expression in classical HLA class I-Negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010; 185:7452-9; PMID:21057081; http://dx.doi.org/10.4049/jimmunol.1002629
   PubMed Web of Science ®Google Scholar
• Wastowski IJ, Simoes RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Jr. et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2′-deoxycytidine and interferon-gamma treatments: results from a multicentric study. Am J Pathol 2013; 182:540-52; PMID:23219427; http://dx.doi.org/10.1016/j.ajpath.2012.10.021
   PubMed Web of Science ®Google Scholar
• Polakova K, Bandzuchova E, Kuba D, Russ G. Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res 2009; 33:518-24; PMID:18823661; http://dx.doi.org/10.1016/j.leukres.2008.08.003
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, del Guercio M-F, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires. J Immunol 1998; 160:3363-73; PMID:9531296
   PubMed Web of Science ®Google Scholar
• Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; http://dx.doi.org/10.1182/blood-2006-10-051318
   PubMed Web of Science ®Google Scholar
• Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep 2007; 18:1463-8; PMID:17982631; http://dx.doi.org/10.3892/or.18.6.1463
   PubMed Web of Science ®Google Scholar
• He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, Li K, Liu J, Chen J. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol 2010; 17:1459-69; PMID:20052552; http://dx.doi.org/10.1245/s10434-009-0891-9
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721-8; PMID:17387718; http://dx.doi.org/10.1002/cncr.22618
   PubMed Web of Science ®Google Scholar
• Torres MI, Le Discorde M, Lorite P, Rios A, Gassull MA, Gil A, Maldonado J, Dausset J, Carosella ED. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol 2004; 16:579-83; PMID:15039388; http://dx.doi.org/10.1093/intimm/dxh061
   PubMed Web of Science ®Google Scholar
• Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 2016; 530:434-40; PMID:26886799; http://dx.doi.org/10.1038/nature16962
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http://dx.doi.org/10.4161/onci.23991
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM. Indoleamine 2, 3-dioxygenase vaccination. OncoImmunology 2015; 4:e983770; PMID:25949864; http://dx.doi.org/10.4161/2162402X.2014.983770
   PubMedGoogle Scholar
• Ketroussi F, Giuliani M, Bahri R, Azzarone B, Charpentier B, Durrbach A. Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One 2011; 6:e22776; PMID:21887223; http://dx.doi.org/10.1371/journal.pone.0022776
   PubMedGoogle Scholar
• Faure M, Long EO. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol 2002; 168:6208-14; PMID:12055234; http://dx.doi.org/10.4049/jimmunol.168.12.6208
   PubMed Web of Science ®Google Scholar
• Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001; 98:12150-5; PMID:11572934; http://dx.doi.org/10.1073/pnas.201407398
   PubMed Web of Science ®Google Scholar
• Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, Carosella ED, Charpentier B, Durrbach A. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 2006; 176:1331-9; PMID:16424159; http://dx.doi.org/10.4049/jimmunol.176.3.1331
   PubMed Web of Science ®Google Scholar
• Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001; 13:193-201; PMID:11157852; http://dx.doi.org/10.1093/intimm/13.2.193
   PubMed Web of Science ®Google Scholar
• Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000; 101:191-200; PMID:11012772; http://dx.doi.org/10.1046/j.1365-2567.2000.00109.x
   PubMed Web of Science ®Google Scholar
• Chen BG, Xu DP, Lin A, Yan WH. NK cytolysis is dependent on the proportion of HLA-G expression. Hum Immunol 2013; 74:286-9; PMID:23238216; http://dx.doi.org/10.1016/j.humimm.2012.12.005
   PubMed Web of Science ®Google Scholar
• Monti P, Leone BE, Zerbi A, Balzano G, Cainarca S, Sordi V, Pontillo M, Mercalli A, Di Carlo V, Allavena P et al. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 2004; 172:7341-9; PMID:15187110; http://dx.doi.org/10.4049/jimmunol.172.12.7341
   PubMed Web of Science ®Google Scholar
• Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116:935-44; PMID:20448110; http://dx.doi.org/10.1182/blood-2009-07-234872
   PubMed Web of Science ®Google Scholar
• Mouillot G, Marcou C, Rousseau P, Rouas-Freiss N, Carosella ED, Moreau P. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 2005; 113:928-36; PMID:15514928; http://dx.doi.org/10.1002/ijc.20682
   PubMed Web of Science ®Google Scholar
• Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci 2003; 100:1191-6; PMID:12552087; http://dx.doi.org/10.1073/pnas.0337539100
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33:1250-9; PMID:12731050; http://dx.doi.org/10.1002/eji.200323730
   PubMed Web of Science ®Google Scholar
• Lich JD, Elliott JF, Blum JS. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med 2000; 191:1513-24; PMID:10790426; http://dx.doi.org/10.1084/jem.191.9.1513
   PubMed Web of Science ®Google Scholar
• Park B, Ahn K. An essential function of tapasin in quality control of HLA-G molecules. J Biol Chem 2003; 278:14337-45; PMID:12582157; http://dx.doi.org/10.1074/jbc.M212882200
   PubMed Web of Science ®Google Scholar
• Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003; 9:4043-51; PMID:14519625
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2:37-49; PMID:24535937; http://dx.doi.org/10.1158/2326-6066.CIR-13-0126
   PubMed Web of Science ®Google Scholar
• Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19:2237-42; PMID:2481588; http://dx.doi.org/10.1002/eji.1830191209
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000; 60:5228-36; PMID:11016652
   PubMed Web of Science ®Google Scholar
• Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer 2013; 109:2155-66; PMID:24045666; http://dx.doi.org/10.1038/bjc.2013.577
   PubMed Web of Science ®Google Scholar
• Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. OncoImmunology 2015; 4:e976077; PMID:25949874; http://dx.doi.org/10.4161/2162402X.2014.976077
   PubMed Web of Science ®Google Scholar